FLIC
South China Morning Post
Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses. Analysts suggest it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and have revised their target prices upwards. The drug’s phase three trial found that ivonescimab reduced the risk of death.
1 vote cast by the community
FLIC Trust Score70 / 100
How FLIC Trust Scores workFLIC Trust Scores turn community ratings into a 0–100 signal about how readers assess a story. Fake News votes lower the score, while Liberal, Conservative, and Independent classifications support it. The formula also rewards a balanced split between Liberal and Conservative ratings instead of treating one political viewpoint as automatically more trustworthy. Scores can change as more people vote and represent community judgment, not a factual verdict or substitute for reading the original reporting. Learn more about how FLIC works.
Open in FLIC App
or
Continue on Web